These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35145519)

  • 1. Intratumor Microbiome Analysis Identifies Positive Association Between
    Huang Y; Zhu N; Zheng X; Liu Y; Lu H; Yin X; Hao H; Tan Y; Wang D; Hu H; Liang Y; Li X; Hu Z; Yin Y
    Front Immunol; 2022; 13():785422. PubMed ID: 35145519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the bile microbiome is associated with progression-free survival in pancreatic ductal adenocarcinoma patients.
    Jiang H; Tian Y; Xu L; Chen X; Huang Y; Wu J; Wang T; Liu T; Wu X; Ye C; Wu H; Ye W; Fang L; Zhang Y
    BMC Microbiol; 2024 Jul; 24(1):235. PubMed ID: 38956452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiome and pancreatic ductal adenocarcinoma.
    Tijeras-Raballand A; Hilmi M; Astorgues-Xerri L; Nicolle R; Bièche I; Neuzillet C
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101589. PubMed ID: 33607375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
    Riquelme E; Zhang Y; Zhang L; Montiel M; Zoltan M; Dong W; Quesada P; Sahin I; Chandra V; San Lucas A; Scheet P; Xu H; Hanash SM; Feng L; Burks JK; Do KA; Peterson CB; Nejman D; Tzeng CD; Kim MP; Sears CL; Ajami N; Petrosino J; Wood LD; Maitra A; Straussman R; Katz M; White JR; Jenq R; Wargo J; McAllister F
    Cell; 2019 Aug; 178(4):795-806.e12. PubMed ID: 31398337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models.
    Thomas RM; Gharaibeh RZ; Gauthier J; Beveridge M; Pope JL; Guijarro MV; Yu Q; He Z; Ohland C; Newsome R; Trevino J; Hughes SJ; Reinhard M; Winglee K; Fodor AA; Zajac-Kaye M; Jobin C
    Carcinogenesis; 2018 Jul; 39(8):1068-1078. PubMed ID: 29846515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
    Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human microbiota colonization and pancreatic ductal carcinoma.
    Fang Y; Yang G; Yang J; Ren J; You L; Zhao Y
    Crit Rev Microbiol; 2023 Aug; 49(4):455-468. PubMed ID: 35924947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the pancreatic cancer microbiome in Mainland China: Impact of Exiguobacterium/Bacillus ratio on tumor progression and prognostic significance.
    Zhang Z; Wang T; Xu M; Zhang Z; Wang H; Xue J; Wang W
    Pharmacol Res; 2024 Jun; 204():107197. PubMed ID: 38692467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma.
    Abe S; Masuda A; Matsumoto T; Inoue J; Toyama H; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Yamakawa K; Gonda M; Masuda S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Ko T; Yokotani Y; Oka Y; Ota S; Kanzawa M; Itoh T; Imai T; Fukumoto T; Hara E; Kodama Y
    J Gastroenterol; 2024 Mar; 59(3):250-262. PubMed ID: 38242997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of intestinal and intratumoral microbiome signatures in genetically engineered mice and human pancreatic ductal adenocarcinoma.
    Pfisterer N; Ammer-Herrmenau C; Antweiler K; Küffer S; Ellenrieder V; Neesse A
    Pancreatology; 2023 Sep; 23(6):663-673. PubMed ID: 37541802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
    Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
    Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
    Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
    Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
    Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
    J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoscopic ultrasound-guided fine-needle biopsy as a tool for studying the intra-tumoral microbiome in pancreatic ductal adenocarcinoma: a pilot study.
    Chu CS; Yang CY; Yeh CC; Lin RT; Chen CC; Bai LY; Hung MC; Lin CC; Wu CY; Lin JT
    Sci Rep; 2022 Jan; 12(1):107. PubMed ID: 34997106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.
    Hrudka J; Lawrie K; Waldauf P; Ciprová V; Moravcová J; Matěj R
    Virchows Arch; 2020 Nov; 477(5):687-696. PubMed ID: 32424767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells.
    Kung PJ; Lai TY; Cao J; Hsu LC; Chiang TC; Ou-Yang P; Tsai CY; Tsai YF; Lin CW; Chen CC; Tsai MK; Tien YW; Lee CY
    Cancer Immunol Immunother; 2022 Mar; 71(3):705-718. PubMed ID: 34374812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.